Inotuzumab Ozogamicin
Showing 26 - 50 of 117
Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP) Trial in France
Unknown status
- Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)
- Inotuzumab ozogamicin (INO)
-
Amiens, France
- +34 more
Aug 10, 2020
Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia
Terminated
- Acute Lymphoblastic Leukemia in Remission
- +2 more
- Cyclophosphamide
- +12 more
-
Houston, TexasM D Anderson Cancer Center
Mar 18, 2021
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma Trial in Houston (biological, drug, other)
Recruiting
- B Acute Lymphoblastic Leukemia
- B Lymphoblastic Lymphoma
- Blinatumomab
- +12 more
-
Houston, TexasM D Anderson Cancer Center
Feb 21, 2021
Reporting of Antibody-Drug Conjugate Associated Sepsis-related
Completed
- Sepsis (SMQ)
- +2 more
- Antibody-Drug Conjugate
- Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
-
Changsha, Hunan, ChinaCentral South University
Jun 19, 2022
Lymphoma, B-Cell Trial in Worldwide (inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone, inotuzumab
Completed
- Lymphoma, B-Cell
- inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone
- inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
-
Gainesville, Florida
- +27 more
Jun 13, 2019
Lymphoma, B-Cell Trial in Aichi, Kanagawa, Tokyo (Inotuzumab Ozogamicin (CMC-544), Rituximab (Rituxan))
Completed
- Lymphoma, B-Cell
- Inotuzumab Ozogamicin (CMC-544)
- Rituximab (Rituxan)
-
Aichi, Japan
- +3 more
Dec 4, 2018
Pediatric and Young Adult B-Cell Malignancies After Commercially
Not yet recruiting
- Lymphoid Leukemia
- Questionnaire for patients receiving therapy
-
Palo Alto, CaliforniaStanford University
May 9, 2023
Leukemia, Acute Lymphoblastic Trial in Worldwide (Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab
Recruiting
- Leukemia, Acute Lymphoblastic
- Omitted Doxorubicin
- +5 more
-
Brussels, Belgium
- +100 more
Dec 12, 2022
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Trial in Israel, United States (Blinatumomab,
Recruiting
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Blinatumomab
- +10 more
-
Anchorage, Alaska
- +152 more
Aug 11, 2022
Cancer Target Therapy Efficacy
Active, not recruiting
- Cancer
- RNA sequencing
- +5 more
-
Walnut, California
- +6 more
Sep 13, 2021
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Gemtuzumab Ozogamicin
- +4 more
-
Baltimore, Maryland
- +1 more
Dec 13, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Acute Myeloid Leukemia Trial in Baltimore (Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs)
Not yet recruiting
- Acute Myeloid Leukemia
- Dose Escalation -tagraxofusp-erzs
- Dose Expansion at RP2D -tagraxofusp-erzs
-
Baltimore, MarylandThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 27, 2023
Acute Myeloid Leukemia Trial in Germany (Venetoclax plus Azacitidine, standard of care chemo plus gemtuzumab ozogamicin)
Not yet recruiting
- Acute Myeloid Leukemia
- Venetoclax plus Azacitidine
- standard of care chemotherapy plus gemtuzumab ozogamicin
-
Essen, NRW, Germany
- +17 more
Jun 6, 2023
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Gemtuzumab Ozogamicin
-
Valhalla, New YorkNew York Medical College
Sep 26, 2022
Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)
Active, not recruiting
- Acute Myeloid Leukemia
- Cladribine
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 10, 2022
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia Trial in United States
Active, not recruiting
- Acute Myeloid Leukemia
- +13 more
- Azacitidine
- Gemtuzumab Ozogamicin
-
Burbank, California
- +176 more
Mar 25, 2022
Acute Myeloid Leukemia Trial in Tampa (Vyxeos, Gemtuzumab Ozogamicin)
Recruiting
- Acute Myeloid Leukemia
- Vyxeos
- Gemtuzumab Ozogamicin
-
Tampa, FloridaMoffitt Cancer Center
Sep 23, 2022
Lymphoma, B-Cell Trial in Worldwide (Inotuzumab ozogamicin [CMC-544])
Completed
- Lymphoma, B-Cell
- Inotuzumab ozogamicin [CMC-544]
-
Birmingham, Alabama
- +21 more
Dec 14, 2018
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody
Active, not recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Anti-OX40 Agonist Monoclonal Antibody PF-04518600
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 25, 2022
B-Cell Lymphoma Trial in Worldwide (inotuzumab ozogamicin, Rituximab)
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +3 more
- Gemtuzumab Ozogamicin
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Houston, TexasM D Anderson Cancer Center
Jun 2, 2021
Acute Lymphoblastic Leukemia Trial in Worldwide (inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high
Completed
- Acute Lymphoblastic Leukemia
- inotuzumab ozogamicin
- +3 more
-
La Jolla, California
- +197 more
Dec 20, 2018
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute
Recruiting
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- +9 more
- Cytarabine
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Oct 27, 2021
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Gemtuzumab Ozogamicin
-
Valhalla, New YorkNew York Medical College
Nov 11, 2021